“Cytokine storm”, not only in COVID-19 patients. Mini-review

Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient’s death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.

• Publication year

  2020

• Venue

  Immunology Letters

• Publication date

  2020-09-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.imlet.2020.09.007PMID 33007369PMCID 7524442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease

  2020cited by this paper
• COVID-19: combining antiviral and anti-inflammatory treatments

  2020cited by this paper
• TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

  2020cited by this paper
• Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome

  2020cited by this paper
• Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

  2020cited by this paper
• Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

  2020cited by this paper
• A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

  2020cited by this paper
• The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

  2020cited by this paper
• American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.

  2019cited by this paper
• Cytokine Release Syndrome: Current Perspectives

  2019cited by this paper
• Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

  2019cited by this paper
• In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy

  2019cited by this paper
• Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study

  2019cited by this paper
• Phenotypes, endotypes and biomarkers in anaphylaxis: current insights

  2018cited by this paper
• Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials

  2018cited by this paper
• Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.

  2018cited by this paper
• Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies.

  2018cited by this paper
• Cytokine release syndrome

  2018cited by this paper
• Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies.

  2017cited by this paper
• Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease

  2017cited by this paper
• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management

  2017cited by this paper
• Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

  2016cited by this paper
• Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

  2016cited by this paper
• Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease

  2016cited by this paper
• Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes.

  2016cited by this paper
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Cromoglycate, not ketotifen, ameliorated the injured effect of warm ischemia/reperfusion in rat liver: role of mast cell degranulation, oxidative stress, proinflammatory cytokine, and inducible nitric oxide synthase

  2015cited by this paper
• Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

  2015cited by this paper
• Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

  2015cited by this paper
• The cytokine storm of severe influenza and development of immunomodulatory therapy

  2015cited by this paper
• The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice

  2015cited by this paper
• Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature

  2015cited by this paper
• Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma

  2014cited by this paper
• In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia

  2014cited by this paper
• The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases

  2013cited by this paper
• Targeting the “Cytokine Storm” for Therapeutic Benefit

  2013cited by this paper
• The effects of erdosteine and N-acetylcysteine on apoptotic and antiapoptotic markers in pulmonary epithelial cells in sepsis.

  2013cited by this paper
• Manumycin A Downregulates Release Of Proinflammatory Cytokines From TNF± Stimulated Human Macrophages

  2012cited by this paper
• Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes.

  2012influential reference
• Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

  2011cited by this paper
• Immunomodulatory therapy for severe influenza

  2011cited by this paper
• N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.

  2010cited by this paper
• Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?

  2010cited by this paper
• Yin and yang of cytokine regulation in solid organ graft rejection and tolerance.

  2008cited by this paper
• Hyperbaric oxygen inhibits stimulus‐induced proinflammatory cytokine synthesis by human blood‐derived monocyte‐macrophages

  2003cited by this paper
• Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide.

  2003cited by this paper
• Interleukin-10 Therapy—Review of a New Approach

  2003cited by this paper
• The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation

  2002cited by this paper
• Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.

  2002cited by this paper
• Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma.

  2001cited by this paper
• Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

  1996cited by this paper
• [Cytokine-mediated biological response to severe infections in surgical patients].

  1996cited by this paper
• Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected].

  1989cited by this paper
• A comparative study on the local inflammatory and immunosuppressive activities of anti-mouse anti-lymphocyte sera.

  1975cited by this paper

• An enzyme-triggered fuse-like microcapsule for encapsulating probiotics: the treatment of ulcerative colitis.

  2026cites this paper
• From rare to more common: The emerging role of omics in improving understanding and treatment of severe inflammatory and hyperinflammatory conditions.

  2025cites this paper
• Vaping-associated illness: a reassessment

  2024cites this paper
• The critical impacts of cytokine storms in respiratory disorders

  2024cites this paper
• Quick Guide to Evolutionary Medicine in Neuroimmunomodulation: Why “Evolved for the Benefit of the Species” Is Not a Valid Argument

  2024cites this paper
• FEATURES OF ULTRASTRUCTURAL CHANGES IN THE LUNGS IN SEVERE COURSE OF COVID-19 INFECTION

  2024cites this paper
• Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches

  2024cites this paper
• SNP (A > G - rs13057211) but not GT(n) polymorphism in HMOX-1 promotor gene is associated with COVID-19 mortality

  2023cites this paper
• ULTRASTRUCTURAL CHANGES IN THE VESSELS OF THE LUNG MICROCIRCULATORY BED IN CORONAVIRUS INFECTION

  2023cites this paper
• IKK2/NFkB signaling controls lung resident CD8+ T cell memory during influenza infection

  2023cites this paper
• Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity.

  2023cites this paper
• A COVID-19 E AS CITOCINAS: UMA REVISÃO DE LITERATURA

  2023cites this paper
• A one-pot and eco-friendly synthesis of novel β-substituted-α-halomethyl acrylates and the bioactivity of these compounds in an in vitro model of mast cell degranulation induced by pro-inflammatory stimuli.

  2023cites this paper
• Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization

  2023cites this paper
• Aloe polymeric acemannan inhibits the cytokine storm in mouse pneumonia models by modulating macrophage metabolism.

  2022cites this paper
• Title-Inflammatory Signaling Pathways in Allergic and Infection-Associated Lung Diseases

  2022cites this paper
• Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza

  2022cites this paper
• Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy

  2022cites this paper
• Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research

  2022cites this paper
• Influenza virus causes lung immunopathology through down-regulating PPARγ activity in macrophages

  2022cites this paper
• COVID-19 vakalarında DNA hasarı ve enflamasyon

  2022cites this paper
• IKK2/NFkB signaling controls lung resident CD8 T cell memory during influenza infection

  2022cites this paper
• Role of p38 mitogen‐activated protein kinase signalling in virus replication and potential for developing broad spectrum antiviral drugs

  2021cites this paper
• Fostering experimental and computational synergy to modulate hyperinflammation

  2021cites this paper
• The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic

  2021cites this paper
• Cytokine Storm and Signaling Pathways: Pathogenesis of SARS-CoV-2 Infection, Managing and Treatment Strategies

  2021cites this paper
• Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond

  2021influential citation
• A Validated Mathematical Model of the Cytokine Release Syndrome in Severe COVID-19

  2021cites this paper
• Sea Urchin Pigments: Echinochrome A and Its Potential Implication in the Cytokine Storm Syndrome

  2021cites this paper
• A Timely Call to Arms: COVID-19, the Circadian Clock, and Critical Care

  2021cites this paper
• Neuronal and Cerebrovascular Complications in Coronavirus Disease 2019

  2020cites this paper